Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
XOMA
$17.85
Xoma
($.15)
(.83%)
XOMA
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus: ($0.19)
Revenue: $4.52 Mil
Thursday
Nov 3
7:30 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, August 04, 2022
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events
What do you expect when XOMA reports earnings?
Beat
Meet
Miss
Where is XOMA's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.
Peers
Vertex Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
Johnson & Johnson
Regeneron Pharmaceuticals
Ultragenyx Pharmaceutical
Eli Lilly
BioMarin Pharmaceutical
Pfizer
Array Technologies
Expectations
›
Xoma